Aytu Biopharma Income Statement (2010-2026) | AYTU

Frequency:

Period:

1Y 3Y 5Y 7Y 10Y All

Values in:

Download Data

Income Statement	Jun2021	Sep2021	Dec2021	Mar2022	Jun2022	Sep2022	Dec2022	Mar2023	Jun2023	Sep2023	Dec2023	Mar2024	Jun2024	Sep2024	Dec2024	Mar2025	Jun2025	Sep2025	Dec2025	Mar2026
Revenue & cost
Revenue (Quarter)	23.48M	21.90M	23.12M	24.20M	27.45M	27.66M	26.28M	22.73M	30.73M	17.82M	18.75M	14.03M	14.59M	16.57M	16.22M	18.45M	15.13M	13.89M	15.16M	12.41M
Cost of Revenue (Quarter)	6.06M	9.30M	9.66M	9.74M	10.01M	10.10M	10.56M	9.99M	12.17M	6.09M	5.22M	3.66M	9.49M	5.66M	5.43M	5.65M	4.78M	5.32M	6.00M	4.81M
Gross Profit (Quarter)	11.30M	12.46M	12.30M	12.69M	14.84M	18.03M	17.29M	12.74M	18.56M	13.04M	14.60M	10.36M	11.05M	11.98M	10.79M	12.81M	10.25M	9.19M	9.62M	7.60M
Operating items
Amortization - Intangibles (Quarter)	1.25M	1.54M	1.50M	1.50M	1.30M	1.20M	1.20M	1.20M	1.20M	0.92M	0.92M	0.92M	0.92M	0.92M	0.92M	0.92M	0.92M	0.44M	0.53M	0.76M
Research & Development (Quarter)	4.76M	1.65M	4.47M	3.28M	3.25M	1.06M	1.71M	0.86M	0.47M	0.59M	0.52M	0.61M	1.04M	0.43M	0.52M	0.16M	0.22M
Selling, General & Administrative (Quarter)	8.55M	8.22M	7.95M	7.62M	7.38M	7.32M	8.02M	7.18M	6.11M	6.29M	4.80M	4.83M	4.03M	5.12M	4.45M	4.11M	3.70M	4.92M	5.07M	4.97M
Restructuring Costs (Quarter)	0.07M											0.24M	1.91M	0.78M	1.32M
Other Operating Expenses (Quarter)	-19.00M	-27.85M	-11.55M	-53.07M	-17.70M	11.45M	14.43M	13.27M	11.82M	7.01M	6.14M	6.27M	6.34M	6.58M	6.19M	6.11M	13.96M	5.77M	6.52M	6.69M
Operating Expenses (Quarter)	35.37M	40.16M	23.59M	66.11M	31.78M	19.84M	24.16M	21.30M	18.39M	13.90M	11.46M	11.96M	13.32M	12.91M	12.48M	10.38M	17.88M	10.69M	11.59M	11.66M
Operating Income (Quarter)	-24.07M	-27.70M	-11.29M	-53.42M	69.81M	-1.81M	-6.87M	-8.56M	13.65M	-0.87M	3.15M	-1.60M	-2.27M	-0.93M	-1.70M	2.42M	-2.69M	-1.50M	-1.97M	-4.06M
EBIT (Quarter)	-24.07M	-27.70M	-11.29M	-53.42M	69.81M	-1.81M	-6.87M	-8.56M	13.65M	-0.87M	3.15M	-1.60M	-2.27M	-0.93M	-1.70M	2.42M	-2.69M	-1.50M	-1.97M	-4.06M
Non-operating items
Non Operating Investment Income (Quarter)
Interest & Investment Income (Quarter)
Other Non Operating Income (Quarter)	-0.49M	-0.04M	-0.26M	0.17M	-0.93M	2.19M	-1.23M	2.57M	8.32M	0.58M	-0.58M	0.07M	-0.60M	0.54M	0.14M	2.26M	1.30M	0.20M	0.19M	-1.26M
Non Operating Income (Quarter)	2.44M	-0.26M	-0.26M	0.13M	-0.76M	-1.08M	-1.23M	-1.22M	3.71M	0.58M	0.10M	0.07M	0.12M	0.54M	0.14M	0.04M	1.30M	0.20M	0.19M	0.15M
Net income details
EBT (Quarter)	-18.74M	-27.96M	-11.55M	-53.29M	-16.09M	-0.70M	-6.69M	-7.20M	-2.46M	-7.47M	1.40M	-1.77M	-2.54M	1.50M	0.38M	3.82M	-19.44M	1.97M	-10.58M	-5.61M
Tax Provisions (Quarter)		-0.11M	-0.00M						0.13M		0.80M	0.50M	0.80M	0.41M	-0.28M	-0.10M	0.44M			0.01M
Profit After Tax (Quarter)	-19.00M	-27.85M	-11.55M	-53.29M	-16.09M	-0.70M	-6.69M	-7.20M	-2.46M	-8.12M	-0.22M	-2.89M	-1.29M	1.47M	0.79M	3.94M	-20.44M	1.97M	-10.58M	-5.62M
Income from Continuing Operations (Quarter)	-18.74M	-27.85M	-11.55M	-53.29M	-16.09M	-0.70M	-6.69M	-7.20M	-2.58M	-7.47M	0.60M	-2.27M	-3.34M	1.09M	0.67M	3.92M	-19.88M	1.97M	-10.58M	-5.62M
Consolidated Net Income (Quarter)	-18.74M	-27.85M	-11.55M	-53.29M	-16.09M	-0.70M	-6.69M	-7.20M	-2.58M	-0.65M	-0.84M	-0.60M	-1.24M	0.38M	0.12M	0.05M	0.06M
Income towards Parent Company (Quarter)	-18.74M	-27.85M	-11.55M	-53.29M	-16.09M	-0.70M	-6.69M	-7.20M	-2.58M	-0.65M	-0.84M	-0.60M	-1.24M	0.38M	0.12M	0.05M	0.06M
Net Income towards Common Stockholders (Quarter)	-18.74M	-27.85M	-11.55M	-53.29M	-16.09M	-0.70M	-6.69M	-7.20M	-2.58M	-0.65M	-0.84M	-0.60M	-1.24M	0.38M	0.12M	0.05M	0.06M
Additional items
EPS (Basic) (Quarter)	-0.77	-21.76	-8.74	-35.90	-5.88	-0.28	-2.15	-1.93	-0.40	-1.48	-0.04	-0.52	-0.22	0.10	0.02	0.01	3.98
EPS (Weighted Average and Diluted) (Quarter)	-0.77	-21.76	-8.74	-35.90	-5.88	-0.28	-2.15	-1.93	-0.40	-1.36	-0.04	-0.41		-0.20	-0.28	0.20		-0.08	-1.05	-0.53
Shares Outstanding (Weighted Average) (Quarter)	16.75M	1.16M	1.30M	1.36M	0.43M	2.52M	3.11M	1.68M	6.54M	6.54M	6.48M	6.48M	3.84M	3.82M	5.90M	5.90M	0.02M	9.44M	10.04M	12.63M
Shares Outstanding (Diluted Average) (Quarter)	16.75M	1.28M	1.30M	1.36M	1.47M	2.52M	3.11M	3.73M	3.34M	5.48M	5.52M	5.53M		9.10M	8.49M	8.61M		19.48M	10.04M	10.51M
EBITDA (Quarter)	-24.07M	-27.70M	-11.29M	-53.42M	69.81M	-1.81M	-6.87M	-8.56M	13.65M	-0.87M	3.15M	-1.60M	-2.27M	-0.93M	-1.70M	2.42M	-2.69M	-1.50M	-1.97M	-4.06M
Interest Expenses (Quarter)										1.28M	1.27M	1.26M	1.25M	0.99M	1.08M	0.90M	0.73M	0.52M	0.56M	0.44M
Tax Rate (Quarter)		0.38%	0.03%						-5.13%		57.18%	-28.30%	-31.53%	27.04%	-74.08%	-2.62%	-2.25%			-0.18%

Research Tools

Aytu Biopharma Income Statement (2010-2026) | AYTU

Create an account

Sign In

Reset Password